Last reviewed · How we verify
Ora Sweet
At a glance
| Generic name | Ora Sweet |
|---|---|
| Sponsor | IWK Health Centre |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH) (PHASE2)
- ONC201 in Pediatric H3 K27M Gliomas (PHASE1)
- Cannabidiol for Bilateral Total Knee Arthroplasty (PHASE4)
- Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 (NA)
- Oral Vancomycin for Preventing Clostridium Difficile Recurrence (PHASE4)
- Verapamil as Therapy for Children and Young Adults With Dravet Syndrome (PHASE2)
- Dexamethasone and Post-tonsillectomy Pain in Children (PHASE4)
- The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ora Sweet CI brief — competitive landscape report
- Ora Sweet updates RSS · CI watch RSS
- IWK Health Centre portfolio CI